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Sexually transmitted diseases (STDs) constitute an epidemic of
tremendous magnitude, with an estimated 15 million persons in
the United States acquiring a new STD each year. Effective clinical
management of STDs is a strategic common element in efforts to
prevent HIV infection and to improve reproductive and sexual
health. Sexually transmitted diseases may result in severe, long-
term, costly complications, including facilitation of HIV infection,
tubal infertility, adverse outcomes of pregnancy, and cervical and
other types of anogenital cancer. The publication of national
guidelines for the management of STDs, by the U.S. Centers for
Disease Control and Prevention (CDC), has been a key component
of federal initiatives to improve the health of the U.S. population
by preventing and controlling STDs and their sequelae. This paper
presents new recommendations from the 2002 CDC Guidelines
for the Treatment of Sexually Transmitted Diseases in the context
of current disease trends and public health.
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Sexually transmitted diseases (STDs) have been calledthe “hidden epidemic” by the U.S. Institute of Medi-
cine (1) because their scope and consequences are under-
recognized by public and health care professionals. In the
United States, STDs constitute an epidemic of tremendous
magnitude, with an estimated 15 million persons acquiring
a new STD each year (2). Reported disease rates, which
grossly underestimate the true burden of infection both
because most STDs are asymptomatic and because of un-
derreporting, echo the huge scope of this epidemic. Two
STDs, chlamydia and gonorrhea, are the first and second
most commonly reported notifiable diseases in the United
States, and they alone made up 80% of the cases of all
notifiable diseases reported to the U.S. Centers for Disease
Control and Prevention (CDC) in 2000 (3). As the Insti-
tute of Medicine has highlighted, reported STD rates in
the United States are the highest in the industrialized
world; in some U.S. communities, they rival those of de-
veloping countries.
Effective clinical management of STDs is a strategic
common element in prevention of HIV infection and in
efforts to improve the health of women, adolescents, and
infants. This is because, if untreated, STDs often result in
severe, long-term, costly complications. These diseases bi-
ologically increase risk for HIV acquisition and HIV trans-
mission at least three- to fivefold (4). They are the leading
preventable cause of involuntary infertility and potentially
fatal ectopic pregnancy, and they play a major role in other
adverse outcomes of pregnancy, ranging from fetal wastage
to low birthweight, prematurity, and congenital infection
(5). One STD, human papillomavirus infection, can cause
cervical and other types of anogenital cancer (6). Indeed,
because STDs are communicable diseases with far-reaching
public health consequences, early detection and treatment
are important, and clinicians can thus play a pivotal role in
improving not only the sexual and reproductive health of
individual patients but also the long-term health and
health care costs of their communities.
In this paper, we examine new recommendations pre-
sented in the 2002 CDC Guidelines for the Treatment of
Sexually Transmitted Diseases (7) (Tables 1 and 2) and
discuss key, ongoing approaches to the treatment of STDs
in the context of current disease trends and public health
needs and opportunities. We highlight the crucial role of
clinicians in reducing the severe, long-term effect of STDs
on adolescents and young adults in the United States.
PREVENTION OF STD-RELATED HIV TRANSMISSION
Because of compelling data linking STD acquisition
and HIV transmission, early detection and appropriate
treatment of STDs are considered key components of a
comprehensive strategy for HIV prevention (8). Among
persons with STDs, those with ulcerative STDs typically
have a higher prevalence of HIV co-infection, reflecting the
fact that ulcerative STDs and HIV infection have shared
risk factors and strong mutually reinforcing effects: Ulcer-
ative STDs can increase HIV transmissibility, and HIV
infection can cause ulcer persistence (4).
Several recent advances have been made in the man-
agement and treatment of genital ulcer disease. In the
United States, most sexually active persons with genital
ulcers have genital herpes, syphilis, or chancroid (9). How-
ever, diagnosis of these conditions on the basis of medical
history and physical examination is often inaccurate unless
accompanied by specific diagnostic testing (10). Therefore,
evaluation of all patients with genital ulcers should include
a serologic test for syphilis and a diagnostic evaluation for
genital herpes; in settings where chancroid is prevalent, a
test for Haemophilus ducreyi should be done. Biopsy of
ulcers may help identify the cause of unusual ulcers or
ulcers that do not respond to initial therapy. Testing for
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HIV should be done in the evaluation of all patients with
genital ulcer disease.
Syphilis
A readily curable, bacterial genital ulcer disease, syph-
ilis continues to be one of the most important STDs be-
cause of its biological effect on HIV acquisition and trans-
mission (4) and its effect on infant health. Currently,
syphilis is an important problem in the southern United
States and in some urban areas in other U.S. regions, and
recent outbreaks have been seen among men who have sex
with men (11, 12). The 2000 rate of primary and second-
ary syphilis, 2.2 per 100 000, is the lowest rate seen since
reporting began in 1941. This historic low rate is comple-
mented by extreme geographic clustering of disease, with
half of all new cases reported from only 22 of the 3115
U.S. counties (1%). These factors have created an un-
precedented opportunity for the elimination of syphilis.
This elimination would address one of our most glaring
ethnic disparities in health and would result in substantial
savings in health care costs. Reported cases of syphilis con-
tinue to disproportionately affect black persons, who had
rates as much as 23 times greater than those in white per-
sons in 2000 (11). The annual direct and indirect costs of
syphilis in the United States are an estimated $966 million,
including the cost of care for adult and congenital syphilis
($214 million) and for HIV infection attributable to syph-
ilis ($752 million) (13). Therefore, the CDC launched a
national plan to eliminate syphilis from the United States
(14). Syphilis elimination has been defined at the national
level as the absence of sustained transmission in the United
States and at the local level as the absence of new cases
within a local jurisdiction (except within 90 days of an
imported index case). The national goal of the syphilis
elimination program is to reduce primary and secondary
syphilis to no more than 1000 cases (0.4 per 100 000 pop-
ulation) and to increase the percentage of syphilis-free
counties to 90% by 2005. Between 1997 and 2000, the
incidence of adult syphilis decreased by 30%, more than a
50% reduction in congenital syphilis was seen, and the
ratio of syphilis rates in black persons to those in white
persons was almost halved (11).
Long-acting preparations of penicillin remain the
treatment of choice for all stages of syphilis. This treatment
is supported by more than 40 years of clinical experience
and a few recent clinical trials (15). Primary, secondary,
and early latent syphilis are effectively treated with a single
dose of 2.4 million units of benzathine penicillin G, while
late latent syphilis requires three benzathine penicillin G
injections given 1 week apart. Persons with HIV infection
who have early syphilis (primary, secondary, or early latent)
should be managed according to these standard treatment
recommendations, but they may be at increased risk for
neurologic complications and may have higher rates of
treatment failure. Management of late latent syphilis in
HIV-infected persons should include a cerebrospinal fluid
examination before treatment. Assessment of therapeutic
efficacy for the various stages of syphilis, regardless of HIV
infection, remains complicated by lack of a well-defined,
consistently observed response in the nontreponemal sero-
logic titer. As a prospective study of early-stage syphilis
recently showed (16), approximately 15% of patients did
not meet standard criteria for serologic cure 12 months
after appropriate treatment; this outcome was not im-
proved by more intensive treatment regimens that provide
extended, high penetration of cerebrospinal fluid. Because
the relation between serologic and clinical response re-
mains unclear in such cases and in the absence of data
supporting greater effectiveness of alternative antimicrobial
regimens, we continue to recommend benzathine penicillin
G for early-stage syphilis, regardless of HIV status.
Despite limited data supporting the use of alternatives
to penicillin in the treatment of early-stage syphilis, the
treatment guidelines suggest several new alternative thera-
pies that seem promising in nonpregnant, penicillin-aller-
gic patients with primary or secondary syphilis. Limited
clinical studies, along with biological and pharmacologic
considerations, suggest that ceftriaxone should be effective
for early-stage syphilis (17), but proper dose, proper dura-
tion of treatment, and efficacy have not been definitively
established. Azithromycin is active against Treponema pal-
lidum in in vitro models and seems to be effective in a
small cohort of patients with early-stage disease, but it may
prove most useful as single-dose therapy for incubating
syphilis (18, 19). In the management of neurosyphilis in
penicillin-allergic persons, ceftriaxone may be considered a
new alternative treatment regimen. The use of any of these
alternatives to penicillin in the treatment of syphilis in
HIV-infected persons has not been well studied.
Genital Herpes
Genital herpes simplex virus type 2 (HSV-2) infection
is the most common infectious cause of genital ulcers in
the United States, with a reported seroprevalence rate of
22% in adults in the early 1990s. This rate represents a
32% increase relative to the previous decade (20). Whereas
most cases of genital herpes are caused by HSV-2, genital
infections with herpes simplex virus type 1 (HSV-1) are
Table 1. New Findings in the Centers for Disease Control and
Prevention 2002 Guidelines for the Treatment of Sexually
Transmitted Diseases
Evaluation for chlamydial infection 3 to 4 months after primary infection
Emergence of quinolone-resistant gonorrhea and implications for treatment
Alternative treatment regimens for early syphilis and neurosyphilis in persons
allergic to penicillin
Commercial availability of type-specific serologic tests for genital herpes
Treatment options for genital herpes in persons with HIV infection
Screening and treatment for bacterial vaginosis before abortion or
hysterectomy to reduce postoperative infectious complications
Nucleic acid testing for human papillomavirus infection in the management
of women with Papanicolaou smears showing atypical squamous cells of
undetermined significance
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Table 2. Selected Recommendations from the Centers for Disease Control and Prevention 2002 Guidelines for the Treatment of
Sexually Transmitted Diseases*
Condition or Need Recommended Treatment Alternatives
Syphilis
Early–primary, secondary, or latent
syphilis, 1 year since infection
Benzathine penicillin G (2.4 million U, IM) in a single
dose
Doxycycline, 100 mg twice daily for 14 d OR
oral tetracycline, 500 mg 4 times daily for 14 d
Late latent syphilis or late syphilis
of unknown duration
Benzathine penicillin G, 3 doses (2.4 million U each, IM)
at 1-week intervals (7.2 million U total)
Doxycycline, 100 mg twice daily for 14 d
OR oral tetracycline, 500 mg 4 times daily for 28 d
Syphilis during pregnancy Benzathine penicillin G at a dosage appropriate for the
stage of syphilis
No proven alternatives
Neurosyphilis Aqueous crystalline penicillin G (3–4 million U, IV) every
4 hours for 10 to 14 d (18 to 24 million U/d)
Procaine penicillin G (2.4 million U, IM) once daily for
10–14 d PLUS oral probenecid, 500 mg 4 times daily for
10–14 d
Genital herpes
First clinical episode Oral acyclovir, 400 mg 3 times daily for 7–10 d OR
Oral acyclovir, 200 mg 5 times daily for 7–10 d OR
Oral famciclovir, 250 mg 3 times daily for 7–10 d OR
Oral valacyclovir, 1 g twice daily for 7–10 d
Episodic recurrences Oral acyclovir, 400 mg 3 times daily for 5 d OR
Oral acyclovir, 200 mg 5 times daily for 5 d OR
Oral acyclovir, 800 mg twice daily for 5 d OR
Oral famciclovir, 125 mg twice daily for 5 d OR
Oral valacyclovir, 500 mg twice daily for 3–5 d OR
Oral valacyclovir, 1.0 g daily for 5 d
Suppression Oral acyclovir, 400 mg twice daily OR
Oral famciclovir, 250 mg twice daily OR
Oral valacyclovir, 500 mg once daily OR
Oral valacyclovir, 1.0 g once daily
Pregnancy See complete CDC guidelines (7)
Genital herpes and HIV infection
Episodic recurrences Oral acyclovir, 400 mg 3 times daily for 5–10 d OR
Oral acyclovir, 200 mg 5 times daily for 5–10 d OR
Oral famciclovir, 500 mg twice daily for 5–10 d OR
Oral valacyclovir, 1.0 g twice daily for 5–10 d
Suppression Oral acyclovir, 400–800 mg 2 or 3 times daily OR
Oral famciclovir, 500 mg twice daily OR
Oral valacyclovir, 500 mg twice daily
Chancroid Oral azithromycin, 1 g in a single dose OR
Ceftriaxone (250 mg, IM) in a single dose OR
Oral ciprofloxacin, 500 mg twice daily for 3 d OR
Oral erythromycin base, 500 mg 3 times daily for 7 d
Chlamydia Oral azithromycin, 1 g in a single dose Oral erythromycin base, 500 g 4 times daily for 7 d OR
Oral doxycycline, 100 mg twice daily for 7 d Oral erythromycin ethylsuccinate, 800 mg 4 times daily for 7
d OR
Oral ofloxacin, 300 mg twice daily for 7 d OR
Oral levofloxacin, 500 mg daily for 7 d
Chlamydia during pregnancy Oral erythromycin base, 500 mg 4 times daily for 7 d
OR
Oral amoxicillin, 500 mg 3 times daily for 7 d
Oral erythromycin base, 250 mg 4 times daily for 14 d OR
Oral erythromycin ethylsuccinate, 800 mg 4 times daily for 7
d OR
Oral erythromycin ethylsuccinate, 400 mg 4 times daily for
14 d OR
Oral azithromycin, 1 g in a single dose
Gonorrhea
Urogenital or rectal gonorrhea† Oral cefixime, 400 mg in a single dose OR Spectinomycin, IM, 2 g in a single dose OR
Ceftriaxone (125 mg, IM) in a single dose OR Single-dose cephalosporin OR
Oral ciprofloxacin, 500 mg in a single dose OR Single-dose quinolone
Oral ofloxacin, 400 mg in a single dose OR
Oral levofloxacin, 250 mg in a single dose PLUS
Treatment for chlamydia if this infection is not ruled out
Bacterial vaginosis
Bacterial vaginosis in nonpregnant
persons
Oral metronidazole, 500 mg twice daily for 7 d OR Oral clindamycin, 300 mg twice daily for 7 d OR
Metronidazole gel 0.75% (one 5-g applicator per day,
intravaginally) for 5 d OR
Clindamycin ovules, 100 g intravaginally for 3 d every
evening OR
Clindamycin cream 2% (one 5-g applicator
intravaginally) for 7 d every evening
Oral metronidazole, 2 g in a single dose
Bacterial vaginosis during
pregnancy
Oral metronidazole, 250 mg 3 times daily for 7 d OR
Oral clindamycin, 300 mg 3 times daily for 7 d
Trichomoniasis Oral metronidazole, 2 g in a single dose Oral metronidazole, 500 mg twice daily for 7 d
* For the complete Centers for Disease Control and Prevention 2002 Guidelines for the Treatment of Sexually Transmitted Diseases, see reference 7 or www.cdc/gov/std/
treatment/default.htm. CDC  Centers for Disease Control and Prevention; IM  intramuscularly; IV  intravenously.
† Quinolones should not be used for infections acquired in Asia or the Pacific, including Hawaii. The use of quinolones is probably inadvisable for the treatment of infections
acquired in California and in other areas with an increased prevalence of quinolone resistance.
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increasingly recognized (21). Most genital herpes infections
are transmitted by persons who are unaware that they have
the infection or are asymptomatic when transmission oc-
curs. In a large population-based study (20), only 9% of
HSV-2–seropositive persons reported that they had genital
herpes. Because of the high proportion of unrecognized
infection, the diagnosis of genital herpes should be con-
firmed by sensitive diagnostic tests, such as viral culture or
HSV type-specific serologic tests. Accurate type-specific as-
says for HSV rely on the detection of antibodies to HSV-
specific glycoprotein G1 and G2. Such assays became com-
mercially available in 1999, but older assays that do not
accurately distinguish HSV-1 antibody from HSV-2 anti-
body remain on the market. The new type-specific assays
are discussed in the CDC’s STD treatment guidelines and
may be useful in the diagnosis of unrecognized infection
and the management of sexual partners of persons with
genital herpes.
Optimal management of genital herpes includes anti-
viral therapy and appropriate counseling on the natural
history of infection, risk for sexual and perinatal transmis-
sion, and methods to prevent further transmission. Sys-
temic antiviral drugs partially control the symptoms and
signs of herpes episodes when used to treat first clinical
episodes and recurrent episodes or when used as daily sup-
pressive therapy. However, these drugs neither eradicate
latent virus nor affect the risk for, frequency of, or severity
of recurrences after use of the drug is discontinued. Effec-
tive antiviral regimens that provide clinical benefit for pa-
tients with genital herpes include acyclovir, valacyclovir,
and famciclovir (22). Suppressive antiviral therapy reduces,
but does not eliminate, subclinical viral shedding (23).
Most genital herpes in HIV-infected persons responds to
antiviral agents, although clinical improvement is often
slower than in immunocompetent persons. Isolates from
patients with persistent HSV infections unresponsive to
antiviral agents should be tested for antiviral resistance.
Clinically significant acyclovir resistance has not emerged
among immunocompetent persons. Additional research is
needed to investigate the extent to which suppressive ther-
apy may prevent HSV transmission, regardless of HIV in-
fection status, and HIV transmission among co-infected
persons.
Chancroid
Chancroid is the ulcerative STD that has been most
strongly linked to HIV transmission (4), and healing of
chancroid may be slowed in persons with HIV infection.
The incidence of chancroid is very low in the United
States, with only 78 cases reported in 2000 (11), but this
disorder is substantially underdiagnosed. Clinicians treat-
ing genital ulcers should be alert to the possibility of chan-
croid, which can be easily treated with single-dose azithro-
mycin or ceftriaxone or with multiday regimens of
ciprofloxacin or erythromycin. Persons with HIV infection
may require longer courses of therapy than those recom-
mended for HIV-negative persons. In addition, data are
limited on the therapeutic efficacy of the recommended
single-dose ceftriaxone or azithromycin regimens in HIV-
infected patients, and these regimens should be used only if
follow-up can be ensured.
PREVENTION OF STD-RELATED INFERTILITY
Prompt recognition and appropriate treatment of chla-
mydial and gonococcal infections are crucial not only in
the prevention of STD-associated HIV transmission but
also in the primary prevention of STD-related infertility.
In women, chlamydial and gonococcal infections are often
asymptomatic. Untreated, they may result in pelvic inflam-
matory disease; this, in turn, results in infertility, ectopic preg-
nancy, and chronic pelvic pain in 10% to 20% of cases (24).
Chlamydia
Chlamydia trachomatis infection is the most common
bacterial STD in the United States, with an estimated 3
million cases occurring annually (2). The highest rates are
in adolescent girls, and studies done in a range of venues,
including secondary schools, family planning clinics, and
the Job Corps, reveal prevalences of chlamydia that usually
range from 4% to 15% (11, 25). Reported rates of chla-
mydial infection have increased dramatically over the past
decade, reflecting expansion of chlamydial screening activ-
ities and the advent of a new generation of highly sensitive
nucleic acid amplification tests. However, many women
who are at risk for chlamydia are still not screened appro-
priately because of lack of awareness among some providers
and limited resources available for screening.
Chlamydia screening and reporting are likely to ex-
pand further in response to the recent screening recom-
mendations from the third U.S. Preventive Services Task
Force (USPSTF) (26) and the inclusion of a chlamydia
screening measure in the Health Plan Employer Data and
Information Set (HEDIS), which assesses the performance
of managed care organizations (27). The USPSTF, the
HEDIS measure, and the STD treatment guidelines rec-
ommend routine screening of all sexually active women 25
years of age or younger and other asymptomatic women at
increased risk for infection (for example, women with new
or multiple sexual partners, a previous STD, or inconsis-
tent use of barrier contraceptives). In parts of the United
States where chlamydia screening and treatment programs
have been widely implemented, rates of positivity for chla-
mydia among women attending family planning clinics
have decreased by as much as two thirds (11). However,
these declines have recently plateaued or reversed in most
of the United States, possibly because of failure to extend
screening coverage to more at-risk women and to men.
This is particularly disturbing because selective chlamydia
screening and treatment in women have been shown to
reduce the incidence of pelvic inflammatory disease (the
critical link between chlamydia and reproductive sequelae)
by almost 60% (28).
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Efficacious regimens for the treatment of chlamydia
include azithromycin or doxycycline. Azithromycin, which
can be given as single-dose, directly observed therapy, may
be the more cost-effective drug in many settings, especially
in persons who are unlikely to complete the 7-day doxy-
cycline regimen (29). A test of cure is not necessary after
completion of treatment with azithromycin or doxycycline
unless symptoms persist or reinfection is suspected. How-
ever, because of the high incidence of new chlamydial in-
fections in women who have had chlamydia in the preced-
ing several months, the new CDC treatment guidelines
suggest rescreening for chlamydia 3 to 4 months after treat-
ment, especially in adolescents.
Gonorrhea
Infections due to Neisseria gonorrhoeae, like those re-
sulting from C. trachomatis, are a major cause of cervicitis,
urethritis, proctitis, and pelvic inflammatory disease. In the
United States, an estimated 650 000 cases of gonorrhea
occur each year (2). The reported gonorrhea rate increased
approximately 10% from 1997 to 1999, after a 72% de-
crease from 1975 to 1997 (11). Because gonococcal infec-
tions in women are often asymptomatic, an important
component of gonorrhea control continues to be the
screening of women at high risk for STDs.
Several antibiotics are effective in the single-dose treat-
ment of gonorrhea, including cefixime, ceftriaxone, cipro-
floxacin, and ofloxacin (7). Concomitant therapy with a
regimen effective against chlamydia is recommended be-
cause of the frequency of dual infections. Recently, quin-
olone-resistant gonorrhea has been reported from southeast
Asia, Hawaii, and California (7, 30). Persons with gonor-
rhea who have recently traveled to Asia or the Pacific, Ha-
waii, and California and persons who have a sexual partner
who has recently traveled to these areas, should receive a
nonquinolone treatment regimen. However, because the
national prevalence of quinolone resistance remains very
low (31), the recommended treatment regimens remain
appropriate for most cases of gonorrhea in the continental
United States and Alaska. The prevalence of quinolone-
resistant gonorrhea may increase in the next several years
because of the importation of infection, and culture and
susceptibility testing should be done in persons with ap-
parent treatment failure. Spectinomycin remains an impor-
tant option for treatment of gonorrhea in cephalosporin-
allergic persons when quinolones cannot be used (for
example, during pregnancy or in areas with a high rate of
quinolone-resistant infections), although availability has re-
cently been a concern (32).
PREVENTION OF STD-RELATED ADVERSE OUTCOMES
OF PREGNANCY
Many sexually transmitted infectious agents are an im-
portant cause of adverse outcomes of pregnancy, including
spontaneous abortion, stillbirth, premature birth, and con-
genital infection (5). Among the ulcerative STDs, syphilis
remains an important cause of illness and death during
pregnancy, despite the widespread availability of inexpen-
sive serologic tests and substantial efforts to encourage rou-
tine screening through early prenatal care. Parenteral pen-
icillin G, if provided at least 1 month before delivery, is
effective in preventing maternal transmission and treating
fetal infection. The appropriate dose and duration of pen-
icillin therapy depend on the clinical stage of syphilis in the
mother. Women with a history of allergy to penicillin
should be desensitized and treated with penicillin; no
proven alternative regimens exist for the treatment of syph-
ilis in pregnancy.
Genital Herpes
The other genital ulcer disease frequently associated
with poor pregnancy outcomes is genital herpes. The risk
for neonatal HSV infection is much greater after first-epi-
sode infection than after reactivation during pregnancy
(33). Primary HSV infection during late pregnancy has
been associated with spontaneous abortion, premature
birth, and low birthweight (34). Prevention of neonatal
herpes depends on preventing herpes acquisition during
late pregnancy and possible exposure of the infant to her-
petic lesions during delivery. Type-specific HSV serologic
screening to identify HSV-negative women has been pro-
posed as a strategy to prevent neonatal herpes, but the
feasibility and effectiveness of this approach are unknown.
Seronegative women at risk for HSV infection should be
counseled to avoid acquiring herpes infection in late preg-
nancy by refraining from genital intercourse with partners
known to have or suspected to have genital herpes and
from direct orogenital contact with partners known to have
or suspected of having orolabial herpes. Antiviral therapy
during pregnancy is recommended in women with primary
HSV infection or severe herpes infection. There seems to
be no increased risk for major birth defects after prenatal
exposure to acyclovir. Data are insufficient to provide use-
ful information on pregnancy outcomes with exposure to
either valacyclovir or famciclovir.
Chlamydia and Gonorrhea
Cervical and vaginal infections also compromise preg-
nancy outcomes. Various studies (35) have inconsistently
linked C. trachomatis infection to premature birth. How-
ever, perinatal infection can result from the acquisition of
chlamydial infection during parturition. Clinical manifes-
tations of neonatal chlamydial infection include inclusion
conjunctivitis, subacute pneumonia, and rectogenital in-
fections. Erythromycin is the recommended regimen for
chlamydial infection in infants. Prenatal screening and
treatment of pregnant women for chlamydia prevents chla-
mydial infection among neonates. Pregnant women who
are younger than 25 years of age or have new or multiple
sex partners should receive the highest priority for chla-
mydia screening.
Gonococcal infection can also affect the health of the
fetus and infant in such ways as premature delivery, pre-
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mature rupture of membranes, and perinatal distress (36).
The most serious manifestations of N. gonorrhoeae infec-
tion in newborns are ophthalmia neonatorum and sepsis,
including arthritis and meningitis. Although N. gonor-
rhoeae is a less frequent cause of ophthalmia neonatorum in
the United States than C. trachomatis and nonsexually
transmitted agents are, this infection is especially impor-
tant because it may result in perforation of the globe of the
eye and blindness. Instillation of a prophylactic agent (sil-
ver nitrate, erythromycin, or tetracycline ointments) into
the eyes of all newborn infants is recommended to prevent
gonococcal ophthalmia neonatorum. Diagnosing and
treating gonococcal infection in pregnant women are the
best ways to prevent neonatal gonococcal disease.
Bacterial Vaginosis
Bacterial vaginosis, a sexually associated infection, has
also been associated with adverse pregnancy outcomes, in-
cluding chorioamnionitis, premature rupture of mem-
branes, premature birth, and postpartum endometritis
(37). Although no national surveillance data are available,
bacterial vaginosis is probably the most prevalent infectious
cause of abnormal vaginal discharge (38). The principal
goal of therapy has been to relieve vaginal symptoms,
which can be accomplished with oral metronidazole, clin-
damycin cream, or metronidazole gel. Treatment trials
show that the oral and vaginal metronidazole regimens are
similarly efficacious and seem to be more effective than
clindamycin cream (7). However, reported cure rates for all
regimens fall short of cure rates for most other reproductive
tract infections. Studies are now under way to evaluate the
efficacy of vaginal lactobacilli suppositories, in addition to
oral metronidazole, for initial treatment and prevention of
recurrent infection. Several studies suggest that treatment
of bacterial vaginosis in pregnant women with a history of
preterm birth may reduce subsequent risk for prematurity
(39, 40). No randomized trial has shown a reduction in
adverse outcomes of pregnancy among asymptomatic
women without a history of preterm birth. Additional
studies are under way to clarify this difficult issue. Current
evidence does not support universal screening for bacterial
vaginosis in pregnancy (41).
Trichomoniasis
Vaginal trichomoniasis has been associated with ad-
verse pregnancy outcomes, but limited data show that
treatment of asymptomatic infection during pregnancy
lessens the association (42). Metronidazole remains the
only recommended treatment for trichomoniasis. Metroni-
dazole use during pregnancy has not been shown to have a
consistent association with teratogenic or mutagenic effects
in the infant. Infections with strains that show diminished
susceptibility to metronidazole can occur. Most nonpreg-
nant women respond to a higher metronidazole dose and
extended therapy. No published data on the use of these
enhanced metronidazole regimens in pregnant women ex-
ist, and pregnant women should be managed in consulta-
tion with an expert in infectious diseases.
PREVENTION OF STD-RELATED CANCER
It is well established that persistent infection with hu-
man papillomavirus (HPV) plays a central role in the
pathogenesis of most types of squamous-cell cancer of the
cervix, vagina, vulva, anus, and penis. Recent estimates of
the cost of treating HPV and cervical cancer exceed $4.5
billion; this is more than the cost of any other single STD
with the exception of HIV infection (1). Most invasive
types of anogenital squamous-cell cancer of the genital
tract and anus have been associated with HPV types 16,
18, 31, or 45, whereas most external genital warts are as-
sociated with HPV types 6 or 11 (6). Subclinical genital
HPV infection occurs more frequently than visible genital
warts and refers to manifestations of infection in the ab-
sence of visible genital warts, including situations where
infection is diagnosed on the basis of characteristic cyto-
logic features, squamous intraepithelial lesions (SIL), or on
any genital skin by a viral nucleic acid (DNA or RNA) or
capsid protein test for HPV. Recognition of the role of
specific HPV types in cervical cancer and the advent of
type-specific HPV tests have stimulated a focus on the use
of HPV diagnostic tests in prevention of cervical cancer.
Testing for HPV was recently proposed as a strategy to
determine which women with low-grade cervical cytologic
abnormalities require colposcopic evaluation. Several trials
designed to clarify the role of HPV testing in the evalua-
tion of low-grade cervical abnormalities indicate that HPV
testing can be useful in the management of women with
Papanicolaou tests that show atypical squamous cells of
undetermined significance, but not in the management of
low-grade SIL (43, 44). At this time, data are insufficient
to recommend routine HPV testing for other clinical pur-
poses. No therapy has been identified that effectively erad-
icates persistent subclinical HPV infection. In the presence
of coexistent SIL, management should be based on histo-
pathologic findings and includes cryotherapy, laser ablation,
cone biopsy, or loop electrosurgical excision procedure.
A strong relation exists among persistent HPV infec-
tion, anal SIL, and anal cancer, showing the same spectrum
of HPV types as those associated with cervical cancer (45).
Prevalence of anal SIL and anal cancer is substantially in-
creased among men who have sex with men and men with
HIV infection (46). Clinicians should be aware of the im-
portance of intra-anal manifestations of HPV infection in
such men, given the association of HPV with anal dyspla-
sia, and they should consider anoscopic examination in
persons with symptoms referable to the anal canal. How-
ever, high-grade anal SIL has been shown in normal-
appearing anal mucosal biopsy specimens from men with
and without HIV infection (47). The appropriate clinical
management for persons with high-grade anal SIL is un-
certain, but ablation or surgical removal has been sug-
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gested. Because of the increased incidence of anal cancer in
HIV-infected men who have sex with men, screening for
anal SIL by anal cytologic examination has been proposed
(48). However, because the natural history of anal SIL has
not been established and management strategies are not
clearly defined, such a screening approach cannot currently
be recommended in the STD treatment guidelines.
CONCLUSIONS
For more than 20 years, the CDC’s publication of
national guidelines for STD management has been a key
component of federal initiatives to improve the health of
the U.S. population by preventing and controlling STDs
and their sequelae. These public health goals can be at-
tained only if they are supported by knowledgeable clini-
cians and if clinicians are, in turn, supported by health care
systems that make it possible for them to deliver optimal
care for patients with STDs and to incorporate new guide-
lines into clinical practice. The 2002 guidelines should
therefore be viewed as the starting point for a process that
requires the ongoing efforts of residency program directors,
providers of continuing medical education, clinic manag-
ers, and health plan administrators in public and private
sectors. As recommendations for STD treatment continue
to evolve in response to basic and clinical research ad-
vances, emerging antimicrobial resistance, and changing
sexual and health care behaviors, clinical practice—at both
the individual and the system level—must reflect these
changes. New, more effective treatment regimens; highly
sensitive screening tests for asymptomatic infection; im-
provements in counseling of patients and their sexual part-
ners; and new vaccines for sexually transmitted pathogens
will benefit individual patients and be crucial to the
achievement of our broader public health goal of improv-
ing sexual and reproductive health in the United States.
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